Category «Idiopathic pulmonary fibrosis»

AK-3280

It’s only fair to share… AK-3280 AK 3280; GDC3280; RG 6069 C19 H15 F3 N4 O2, 388.34 CAS 1799412-33-1 4H-Benzimidazol-4-one, 1,5-dihydro-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-[4-(trifluoromethoxy)phenyl]- Ci8Hi4N502F3, mass 389.3 g/mol), ROCHE, Ark Biosciences , under license from Roche , is developing AK-3280, an antifibrotic agent, for the potential oral treatment of IPF. In July 2018, Ark intended to further clinical development of the drug, for IPF. …

Tanzisertib

It’s only fair to share… Tanzisertib CAS 899805-25-5 trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol C21-H23-F3-N6-O2, 448.4467 9557 Cyclohexanol, 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-, trans- CC 930 CC-930 Tanzisertib UNII-M5O06306UO A c-Jun amino-terminal kinase inhibitor.UNII, M5O06306UO Treatment of Idiopathic Pulmonary Fibrosis (IPF) Originator Celgene Corporation Class Antifibrotics; Small molecules Mechanism of ActionJ NK mitogen-activated protein kinase inhibitors Orphan Drug Status Yes – Idiopathic pulmonary fibrosis Discontinued Discoid lupus erythematosus; …

HEC-68498

It’s only fair to share…   HEC-68498, CT-365 CAS 1621718-37-3 C20 H13 F2 N5 O3 S 441.41 Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- N-[5-(3-Cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluorobenzenesulfonamide HEC Pharm , Calitor Sciences Llc; Sunshine Lake Pharma Co Ltd PHASE 1, idiopathic pulmonary fibrosis and solid tumors Phosphoinositide 3-kinase inhibitor; mTOR inhibitor Originator HEC Pharm Developer HEC Pharm; Sunshine Lake Pharma Class Anti-inflammatories; Antifibrotics; Isoenzymes Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors …